Vitamin B12 for Pernicious Anemia

Verdict: Published

Across 5 PubMed studies, the evidence for Vitamin B12 in Pernicious Anemia grades Tier A — moderate evidence.

A 🔵 A Moderate Evidence Published

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.79
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published
Confidence
93%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.75
L11 AI re-checkIndependent read
0.80
L2 PubMedPrimary literature
0.85
L5 Clinical bodiesAuthoritative stance
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.785
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency
PMID: 16034940 2005 Cochrane Review n = 108
Finding: Pooling 2 RCTs (108 randomized, 93 followed 90 days-4 months), high-dose oral B12 (1000-2000 mcg/day) was judged as effective as intramuscular B12 for short-term haematological and neurological response, though the abstract reported no pooled effect size due to the very limited evidence base.
🟢 High quality Government Effect size: No pooled MD/CI reported (only 2 trials; narrative 'as effective')
View on PubMed
Effective treatment of cobalamin deficiency with oral cobalamin
PMID: 9694707 1998 RCT (open-label) n = 38
Finding: In 38 newly diagnosed cobalamin-deficient patients randomized to oral 2 mg/day vs IM (18 vs 15 analyzed), oral therapy produced HIGHER mean serum cobalamin at 4 months (1005 vs 325 pg/mL, P<.0005) with haematologic and neurologic correction prompt and indistinguishable between groups.
Government Effect size: Serum cobalamin mean difference +680 pg/mL favoring oral (1005 vs 325 pg/mL), P<.0005
View on PubMed
Efficacy of different routes of vitamin B12 supplementation for the treatment of patients with vitamin B12 deficiency: A systematic review and network meta-analysis
PMID: 38231320 2024 統合分析 n = 4,275
Finding: Across 13 studies (4275 patients), all of oral, IM and sublingual B12 effectively raised serum B12 with no statistically significant difference between routes; IM ranked numerically first (MD 94.09 pg/mL vs oral) and sublingual second (MD 43.31 pg/mL), but neither reached significance.
Effect size: IM vs oral MD = 94.09 pg/mL (NS); sublingual vs oral MD = 43.31 pg/mL (NS)
View on PubMed
Systematic Review and Pragmatic Clinical Approach to Oral and Nasal Vitamin B12 (Cobalamin) Treatment in Patients with Vitamin B12 Deficiency Related to Gastrointestinal Disorders
PMID: 30261596 2018 系統性回顧
Finding: Synthesizing 4 RCTs (vs IM), 13 prospective studies and 8 reviews, oral B12 1000 mcg/day adequately normalized serum B12 and was an effective alternative to intramuscular B12, EXCEPT in patients with severe neurological manifestations; conclusion is narrative/pragmatic with no pooled effect size.
Effect size: None reported (narrative synthesis)
View on PubMed
The Immunomodulatory Effect of Vitamin B12 in Pernicious Anemia: A Systematic Review
PMID: 40458194 2025 系統性回顧
Finding: B12 administration shifted immune markers toward normal (restored CD3/CD8+/CD19, improved NK-cell activity, lowered CD4/CD8 ratio), but the review reported no sample size, no effect sizes or significance, assessed only surrogate immune markers (not anemia/symptom correction), and called for Phase II/III trials.
🟠 Limited quality Effect size: None reported (no quantitative pooling; surrogate markers only)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
NUTRIENT SUPPLEMENT source↗
L4b EU EFSA
Supportive
a cause and effect relationship has been established source↗
L4c UK NHS
Supportive
Adults aged 19 to 64 need about 1.5 micrograms a day of vitamin B12. source↗
L4d TW TFDA / 衛福部
Supportive
維生素B12之足夠攝取量(AI)成人為每日2.4微克 source↗
L4e WHO
Supportive
Vitamin B12 or folate supplementation during pregnancy is not recommended as an intervention to improve maternal and infant health outcomes source↗
L5a NIH Office of Dietary Supplements
Supportive
Vitamin B12 supplementation appears to have no beneficial effect on performance in the absence of a nutritional deficit. source↗
L5b Mayo Clinic
Supportive
For pernicious anemia, you most often get vitamin B-12 in a shot, and you may need to keep getting the shot for the rest of your life. If you are using vitamin B-12 medicine to treat vitamin B-12 deficiency caused by pernicious anemia, you will need to use the medicine for the rest of your life. source↗
L5c Cleveland Clinic
Supportive
Since vitamin B12 absorption is blocked, your healthcare provider may prescribe intramuscular vitamin B12 injections. Later, after B12 stores are back to normal, they may prescribe high doses of oral B12 replacement. Most people who have pernicious anemia take vitamin B12 supplements for the rest of their lives. source↗
L5d Harvard Health
Supportive
People with pernicious anemia or people who cannot absorb vitamin B12 from their intestines will need injections of vitamin B12 every one to three months indefinitely. Sometimes people can take high doses of oral B12 to provide replacement instead of undergoing injections, but a physician should closely supervise this. source↗
L5e Specialty Society (condition-mapped)
Supportive
Patients suspected of having pernicious anaemia should be tested for intrinsic factor antibody. Patients found to be positive should have lifelong therapy with cobalamin (Grade 1A). Treatment of established cobalamin deficiency should follow the schedules in the British National Formulary (Grade 1A). Initial treatment with oral cobalamin may not be appropriate in pernicious anaemia, but may be … source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-pernicious-anemia-INT-vitamin-b12-001 繁體中文版 →